Conferences
ASCO GU 2024: Prognostic Value of AI–Driven Tumor Estimation of PSMA PET Total Tumor Burden in Newly Diagnosed High-Volume mHSPC
January 28, 2024
ASCO GU 2024: OASIS: Survival Outcomes of Apalutamide as a Starting Treatment - Impact in Real-World Patients with mCSPC
January 28, 2024
ASCO GU 2024: ProstAct-SELECT: Safety, Tolerability, and Dosimetry of 177Lu-TLX591 with Best Standard of Care in Patients with PSMA-Expressing mCRPC
January 28, 2024
ASCO GU 2024: Real-world Treatment Sequences and Time to Discontinuation in the First-line mCRPC Setting
January 28, 2024
ASCO GU 2024: Population Based Trends in Intravesical Gemcitabine Use Among Patients with High-Risk Non-Muscle Invasive Bladder Cancer
January 28, 2024
ASCO GU 2024: Reasons for Refusal of or Ineligibility for Radical Cystectomy in Patients with BCG–unresponsive High-Risk NMIBC from the SunRISe-1 Study
January 28, 2024
ASCO GU 2024: SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-tumor Efficacy of 67CU-Sar-Bispsma in Patients With mCRPC
January 28, 2024
ASCO GU 2024: Insights from CheckMate 67T and Patient-Reported Outcomes in LITESPARK-005 for Advanced RCC
January 28, 2024